Literature DB >> 11409851

Expression of VACM-1 protein in cultured rat adrenal endothelial cells is linked to the cell cycle.

A Zeneberg, A Roulo, J Grobe, P Zhao, P I Lelkes, P Clare, C Barney.   

Abstract

The vasopressin-activated calcium-mobilizing (VACM-1) protein is a unique arginine vasopressin (AVP) receptor which shares sequence homology with the cullins, genes involved in the regulation of cell cycle transitions. Unlike either cullins or AVP receptors, however, VACM-1 is expressed exclusively in the vascular endothelial cells and in the renal collecting tubule cells. In order to test the hypothesis that the expression of VACM-1 might be correlated with the cell cycle, and to establish an endothelial cell model for the VACM-1 receptor, we examined VACM-1 expression in rat adrenal medulla endothelial cells (RAMEC). Northern and Western blot analyses of mRNA and protein from RAMEC identified presence of 6.4 kb mRNA and a Mr 81 kDa protein, respectively. Immunostaining of RAMEC with anti-VACM-1 antibodies and Western blot analyses indicated that in RAMEC, VACM-1 protein expression is dependent on the cell cycle. VACM-1 protein virtually disappears during the S phase and localizes to the cytosol during cell division and to the cell membrane at the completion of cytokinesis. Furthermore, pretreatment of RAMEC with anti-VACM-1 specific antibodies increased basal levels of Ca2+and attenuated the AVP-dependent increase in cytosolic Ca2+. In summary, these results indicate that VACM-1 protein expression in RAMEC membrane is linked to the cell cycle, and consequently, VACM-1 may be involved in the regulation of cell division.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2001        PMID: 11409851     DOI: 10.3109/10623320109063157

Source DB:  PubMed          Journal:  Endothelium        ISSN: 1026-793X


  7 in total

1.  Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent.

Authors:  Nicole K Littlejohn; Rick B Siel; Pimonrat Ketsawatsomkron; Christopher J Pelham; Nicole A Pearson; Aline M Hilzendeger; Beth A Buehrer; Benjamin J Weidemann; Huiping Li; Deborah R Davis; Anthony P Thompson; Xuebo Liu; Martin D Cassell; Curt D Sigmund; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-27       Impact factor: 3.619

2.  Phosphorylation of VACM-1/Cul5 by protein kinase A regulates its neddylation and antiproliferative effect.

Authors:  Shirley E Bradley; Alyssa E Johnson; Isabelle P Le; Elizabeth Oosterhouse; Michael P Hledin; Gabriel A Marquez; Maria Burnatowska-Hledin
Journal:  J Biol Chem       Date:  2009-11-16       Impact factor: 5.157

3.  SENP8 limits aberrant neddylation of NEDD8 pathway components to promote cullin-RING ubiquitin ligase function.

Authors:  Kate E Coleman; Miklós Békés; Jessica R Chapman; Sarah B Crist; Mathew Jk Jones; Beatrix M Ueberheide; Tony T Huang
Journal:  Elife       Date:  2017-05-05       Impact factor: 8.140

4.  Cullin-5 (CUL5) as a potential prognostic marker in a pan-cancer analysis of human tumors.

Authors:  Zian Li; Nan Hu; Lirui Dai; Xuelei Hou; Weihua Hu; Wulong Liang; Xinjun Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Analysis of CUL-5 expression in breast epithelial cells, breast cancer cell lines, normal tissues and tumor tissues.

Authors:  Michael J Fay; Kenneth A Longo; George A Karathanasis; David M Shope; Craig J Mandernach; Jason R Leong; Alfred Hicks; Kenneth Pherson; Amyna Husain
Journal:  Mol Cancer       Date:  2003-11-25       Impact factor: 27.401

Review 6.  The role of cullin 5-containing ubiquitin ligases.

Authors:  Fumihiko Okumura; Akiko Joo-Okumura; Kunio Nakatsukasa; Takumi Kamura
Journal:  Cell Div       Date:  2016-03-09       Impact factor: 5.130

7.  CUL5 is required for thalidomide-dependent inhibition of cellular proliferation.

Authors:  Bryan Kunkler; Daniel Salamango; Zachary J DeBruine; Caitlin Ploch; Shirley Dean; David Grossens; Michael P Hledin; Gabriel A Marquez; Julie Madden; Abigayle Schnell; Michael Short; Maria A Burnatowska-Hledin
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.